Discontinued — last reported Q4 '22
Alnylam Pharmaceuticals Convertible debentures increased by 0.2% to $1.01B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 1.6%, from $1.03B to $1.01B.
An increase indicates reliance on convertible financing, which may lead to future shareholder dilution upon conversion.
This represents the long-term portion of debt instruments that can be converted into a predetermined number of the compa...
High-growth software companies frequently utilize convertible notes to fund expansion while managing interest expense.
other_convertible_debt_noncurrent| Q4 '21 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $1.02B | $1.02B | $1.02B | $1.02B | $1.02B | $1.02B | $1.02B | $1.02B | $1.02B | $1.02B | $1.03B | $1.03B | $1.04B | $1.01B | $1.01B |
| QoQ Change | — | — | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +0.1% | +1.3% | -3.1% | +0.2% |
| YoY Change | — | — | — | — | — | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | +0.4% | +1.6% | -1.6% | -1.6% |